Press coverage about DBV Technologies (NASDAQ:DBVT) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DBV Technologies earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5197009451612 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Short Interest in DBV Technologies SA – (DBVT) Increases By 28.3% (americanbankingnews.com)
- DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company (finance.yahoo.com)
- Brokerages Anticipate DBV Technologies SA – (DBVT) Will Post Quarterly Sales of $2.77 Million (americanbankingnews.com)
- -$1.15 EPS Expected for DBV Technologies SA – (DBVT) This Quarter (americanbankingnews.com)
Shares of DBV Technologies (DBVT) opened at $23.00 on Wednesday. DBV Technologies has a one year low of $20.08 and a one year high of $50.57.
ILLEGAL ACTIVITY WARNING: “DBV Technologies (NASDAQ:DBVT) Receiving Somewhat Favorable Media Coverage, Report Shows” was first reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/14/dbv-technologies-dbvt-getting-somewhat-positive-news-coverage-study-shows/1971237.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.